Despite the high prevalence of t(14;18) and the associated overexpression of BCL2 seen in FL, clinical data have demonstrated inferior efficacy with BCL2 inhibition compared to CLL/SLL or MCL. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.